Patent details
EP4132930 Title: CRYSTALLINE FORMS OF (9, 135S)-13- {4-[5-CHLORO-2-(4-CHLORO-1H,2,3- TRIAZOL- 1 -YL)PHENYL] -6-OXO- 1,6-DIHYDROPYRIMIDIN- 1-YL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15- TETRAAZATRICYCLO [ 12.3.1.0] OCTADECA- 1(18), 2(6), 4, 14, 16-PENTAEN-8-ONE
Basic Information
- Publication number:
- EP4132930
- PCT Application Number:
- US2021026663
- Type:
- European Patent Granted for LU
- Legal Status:
- In force
- Application number:
- EP217220854
- PCT Publication Number:
- WO2021207659
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- CRYSTALLINE FORMS OF (9, 135S)-13- {4-[5-CHLORO-2-(4-CHLORO-1H,2,3- TRIAZOL- 1 -YL)PHENYL] -6-OXO- 1,6-DIHYDROPYRIMIDIN- 1-YL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15- TETRAAZATRICYCLO [ 12.3.1.0] OCTADECA- 1(18), 2(6), 4, 14, 16-PENTAEN-8-ONE
- French Title of Invention:
- FORMES CRYSTALLINES DE (9R,135S)-13-{4-[5-CHLORO-2-(4-CHLORO-1H,2,3-TRIAZOL-1-YL)PHÉNYL]-6-OXO-1,6-DIHYDROPYRIMIDIN-1-YL}-3-(DIFLUOROMÉTHYL)-9-MÉTHYL-3,4,7,15-TÉTRAAZATRICYCLO[12.3.1.0]OCTADÉCA-1(18),2(6),4,14,16-PENTAEN-8-ONE
- German Title of Invention:
- KRISTALLINE FORMEN VON 9, 125S)-13-{4-[5 -CHLOR-2-(4-CHLOR-1H,2,3-TRIAZOL-1 -YL)PHENYL!-6-OXO-1,6-DIHYDROPYRIMIDIN-1-YL}-3-(DIFLUORMETHYL)-9-METHYL-3,4,15-TETRAAZATRICYCLO[1,2.1.0!OCTADECA
- SPC Number:
Dates
- Filing date:
- 09/04/2021
- Grant date:
- 20/05/2026
- EP Publication Date:
- 15/02/2023
- PCT Publication Date:
- 14/10/2021
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 20/05/2026
- EP B1 Publication Date:
- 20/05/2026
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 09/04/2041
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 13/05/2026
- Name:
- Bristol-Myers Squibb Company
- Address:
- Route 206 and Province Line Road, Princeton, NJ 08543, United States (US)
- Name:
- JANSSEN Pharmaceutica NV
- Address:
- Turnhoutseweg 30, 2340 Beerse, Belgium (BE)
Inventor
1
- Name:
- LÜDEKER, David
- Address:
- Belgium (BE)
2
- Name:
- AHUJA, Dipali
- Address:
- Belgium (BE)
3
- Name:
- CLEEREN, Dirk Angelina J.
- Address:
- Belgium (BE)
4
- Name:
- ZIEMBA, Theresa M.
- Address:
- United States (US)
5
- Name:
- SMITH, Daniel
- Address:
- United States (US)
6
- Name:
- XIOURAS, Christos
- Address:
- Belgium (BE)
7
- Name:
- GALELLA, Michael A.
- Address:
- United States (US)
8
- Name:
- DILGER, Andrew K.
- Address:
- United States (US)
Priority
- Priority Number:
- 202063008161 P
- Priority Date:
- 10/04/2020
- Priority Country:
- United States (US)
Classification
- IPC classification:
- C07D 471/18; A61P 7/02; A61K 31/439;
Publication
European Patent Bulletin
- Issue number:
- 202621
- Publication date:
- 20/05/2026
- Description:
- Grant (B1)
Annual Fees
- Annual Fee Due Date:
- 30/04/2027
- Annual Fee Number:
- 7
- Annual Fee Amount:
- 82 Euro
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|